financetom
Business
financetom
/
Business
/
Agilysys Off to 'Fast Start' After Strong Fiscal Q4, Upbeat Subscription Revenue Outlook, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Agilysys Off to 'Fast Start' After Strong Fiscal Q4, Upbeat Subscription Revenue Outlook, Oppenheimer Says
May 14, 2024 10:12 AM

12:41 PM EDT, 05/14/2024 (MT Newswires) -- Agilysys' ( AGYS ) better-than-expected subscription revenue growth guidance of 27% for fiscal year 2025 following its strong fiscal Q4 financial results suggests a "fast start," Oppenheimer said in a note Tuesday.

The company's "very solid" fiscal Q4 results were driven by record annual contract value, accelerating subscription revenue growth, and a 47% free cash flow margin, according to analysts.

Aside from these "impressive" results and the company's upbeat outlook for fiscal year 2025, the firm said it also expects a large inflection to Agilysys' ( AGYS ) subscription revenue growth in fiscal 2026 when cloud-native property management system software for Marriot International (MAR) goes live.

Product revenue, however, is declining and could impact margin improvements as customers prefer to use mobile devices instead of point-of-sale terminals, Oppenheimer said.

Agilysys' ( AGYS ) increased business momentum due to its fast subscription revenue and profitable growth still makes the company "a good growth compounder which should support multiples expansion," the note said.

Oppenheimer raised the price target on Agilysys ( AGYS ) to $100 from $95 and kept its outperform rating.

The company's shares were up nearly 14% in recent trading.

Price: 91.37, Change: +11.16, Percent Change: +13.91

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
Nov 13, 2024
On Wednesday, BioNTech SE ( BNTX ) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases. With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. Also Read: BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts...
--Archer-Daniels-Midland Compliance Chief Leaves Amid Accounting Probe, Bloomberg Reports
--Archer-Daniels-Midland Compliance Chief Leaves Amid Accounting Probe, Bloomberg Reports
Nov 13, 2024
01:14 PM EST, 11/13/2024 (MT Newswires) -- Price: 51.85, Change: +0.41, Percent Change: +0.81 ...
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis
Nov 13, 2024
On Wednesday, Aileron Therapeutics Inc ( ALRN ) revealed topline data from Cohort 2 of its Phase 1b trial of safety and tolerability of inhaled LTI-03 for idiopathic pulmonary fibrosis (IPF). LTI-03 is a novel, Caveolin-1-related peptide that modulates profibrotic activity and sustains critical alveolar epithelial cells. Following inhaled administration of high dose LTI-03 (5 mg BID), a positive trend was observed...
Market Chatter: Meta to Launch Ads on Threads Platform in Early 2025
Market Chatter: Meta to Launch Ads on Threads Platform in Early 2025
Nov 13, 2024
01:05 PM EST, 11/13/2024 (MT Newswires) -- Meta Platforms ( META ) plans to launch advertisements on its social media platform, Threads, in early 2025, The Information reported Wednesday, citing three people with direct knowledge of the matter. Meta didn't immediately respond to a request for comment from MT Newswires. (Market Chatter news is derived from conversations with market professionals...
Copyright 2023-2026 - www.financetom.com All Rights Reserved